Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the initiation of PHALCON-EE, the Company’s pivotal Phase 3 clinical trial of vonoprazan for both the healing and maintenance of healing of erosive esophagitis (EE) as well as the relief of heartburn.
Sensorion’s SENS-111 (Seliforant) has failed to meet primary endpoint in the phase 2b proof-of-concept trial to treat acute unilateral vestibulopathy (AUV).
French company MedinCell (Paris:MEDCL) and the Bill & Melinda Gates Foundation have signed an agreement for up to an additional $19 million to be granted over four years.
EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced positive results from the Phase 1 G-FORCE trial of RRx-001 as first-line treatment in newly diagnosed glioblastoma
Roche said that Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) improved the overall survival in a phase 3 trial in patients with unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.
Sangamo Therapeutics, a genomic medicine company, announced today that the United Kingdom’s (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted authorization of the first-in-human clinical trial to evaluate a Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) therapy.
The Medicines Company announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical studies of inclisiran, an investigational twice-yearly therapy to reduce LDL-C and the first and only cholesterol-lowering treatment in the siRNA (small-interfering RNA) class.
GlaxoSmithKline (GSK) said that its respiratory drug Nucala (mepolizumab) has succeeded in reducing flares in patients with hypereosinophilic syndrome (HES) in a phase 3 study.
Boehringer Ingelheim and Eli Lilly have commenced first ever trial to evaluate Jardiance (empagliflozin) in people hospitalised for acute heart failure who have been stabilised.
Roche said that part 2 of the SUNFISH trial assessing risdiplam for the treatment of Type 2 or 3 spinal muscular atrophy (SMA) in people aged 2-25 years has met its primary endpoint.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.